PE20220342A1 - Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll - Google Patents
Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo tollInfo
- Publication number
- PE20220342A1 PE20220342A1 PE2022000076A PE2022000076A PE20220342A1 PE 20220342 A1 PE20220342 A1 PE 20220342A1 PE 2022000076 A PE2022000076 A PE 2022000076A PE 2022000076 A PE2022000076 A PE 2022000076A PE 20220342 A1 PE20220342 A1 PE 20220342A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- imidazo
- ethoxymethyl
- diol
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a compuestos imidazo-piridinilo de formula (I), R1 y R2 son C1-3 alquilo; o R1 y R2 se unen para formar un anillo carbociclico de 5 a 7 miembros, en donde dicho anillo carbociclico puede ser saturado o insaturado; R3 es -CH2-CR2(CH2-OH)-CH2-O-R6; R4 es C1-6 alquilo, o (CH2)nO(CH2)mCH3, en donde el C1-6 alquilo o cualquier carbono del grupo (CH2)nO(CH2)mCH3 se sustituye con 0 a 3 halogenos, como lo permita la valencia; R5 es C1-3 alquilo, u OC1-3 alquilo, en donde C1-3 alquilo se sustituye con 0 a 3 F; R6 es H, o C1-3 alquilo, en donde C1-3 alquilo se sustituye con 0 a 3 F; m es 0 a 2; y n es 1 a 3. Son compuestos preferidos: 2-((4-amino-2-(etoximetil)-6,7-dimetil-1H-imidazo[4,5-c]piridin-1-il)metil)-2- metilpropan-1,3-diol; 2-((4-amino-2-(etoximetil)-1H-imidazo[4,5-c]quinolin-1-il)metil)-2- metilpropan-1,3-diol; 2-((4-amino-2-(etoximetil)-7,8-dihidrociclopenta[b]imidazo[4,5-d]piridin1(6H)-il)metil)-2-metilpropan-1,3-diol; entre otros. Dichos compuestos son utiles para el tratamiento de crecimiento celular anormal, que incluye cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962875465P | 2019-07-17 | 2019-07-17 | |
US202062961288P | 2020-01-15 | 2020-01-15 | |
PCT/IB2020/056605 WO2021009676A1 (en) | 2019-07-17 | 2020-07-14 | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20220342A1 true PE20220342A1 (es) | 2022-03-14 |
Family
ID=71728839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000076A PE20220342A1 (es) | 2019-07-17 | 2020-07-14 | Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll |
Country Status (20)
Country | Link |
---|---|
US (2) | US11339159B2 (es) |
EP (1) | EP3999507A1 (es) |
JP (1) | JP7137733B2 (es) |
KR (1) | KR20220034862A (es) |
CN (1) | CN114364677A (es) |
AU (1) | AU2020315210B2 (es) |
BR (1) | BR112022000341A2 (es) |
CA (1) | CA3147266C (es) |
CL (1) | CL2022000032A1 (es) |
CO (1) | CO2022000259A2 (es) |
CR (1) | CR20220018A (es) |
CU (1) | CU20220003A7 (es) |
EC (1) | ECSP22003665A (es) |
IL (1) | IL289877A (es) |
MX (1) | MX2022000656A (es) |
PE (1) | PE20220342A1 (es) |
TW (1) | TWI755788B (es) |
UY (1) | UY38786A (es) |
WO (1) | WO2021009676A1 (es) |
ZA (1) | ZA202201330B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Her2を標的とする免疫結合体 |
US11339159B2 (en) * | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
WO2022153157A1 (en) | 2021-01-13 | 2022-07-21 | Pfizer Inc. | A crystalline form of 2-((4-amino-2-(ethoxymethyl)-6,7-dimethyl-1 h-imidazo[4,5-c]pyridin-1-yl)methyl)-2-methylpropane-1,3-diol free base |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
CA2167042A1 (en) | 1993-07-15 | 1995-01-26 | Kyle J. Lindstrom | Imidazo[4,5-c]pyridin-4-amines |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
AR046046A1 (es) | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
US20070259881A1 (en) | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
US8846710B2 (en) * | 2005-02-23 | 2014-09-30 | 3M Innovative Properties Company | Method of preferentially inducing the biosynthesis of interferon |
US8436178B2 (en) | 2007-05-08 | 2013-05-07 | Astrazeneca Ab | Imidazoquinolines with immuno-modulating properties |
EP3239178A1 (en) | 2007-12-14 | 2017-11-01 | Bristol-Myers Squibb Company | Binding molecules to the human ox40 receptor |
SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
MY168297A (en) | 2011-11-17 | 2018-10-23 | Pfizer | Cytotoxic Peptides and Antibody Drug Conjugates Thereof |
AR100137A1 (es) | 2014-04-22 | 2016-09-14 | Hoffmann La Roche | Compuestos 4-amino-imidazoquinolina |
WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
CA2963717C (en) | 2014-12-08 | 2023-10-10 | F. Hoffmann-La Roche Ag | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection |
KR102405104B1 (ko) | 2015-04-13 | 2022-06-07 | 화이자 인코포레이티드 | 치료 항체 및 그의 용도 |
ES2848648T3 (es) | 2015-12-14 | 2021-08-11 | Glaxosmithkline Biologicals Sa | Imidazoquinolinas pegiladas como agonistas de TLR7 y TLR8 |
CN109563081A (zh) | 2016-04-07 | 2019-04-02 | 葛兰素史克知识产权开发有限公司 | 可用作蛋白调节剂的杂环酰胺类 |
HRP20220936T1 (hr) | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterociklički amidi korisni kao modulatori proteina |
US10533007B2 (en) * | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
WO2018093967A1 (en) | 2016-11-16 | 2018-05-24 | Wink Robotics | Method and device for evaluation of eyelashes |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
TWI790120B (zh) | 2017-06-02 | 2023-01-11 | 美商輝瑞大藥廠 | 對flt3具特異性之抗體及其用途 |
MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
US11339159B2 (en) * | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
-
2020
- 2020-07-13 US US16/926,933 patent/US11339159B2/en active Active
- 2020-07-14 PE PE2022000076A patent/PE20220342A1/es unknown
- 2020-07-14 BR BR112022000341A patent/BR112022000341A2/pt unknown
- 2020-07-14 CN CN202080065174.XA patent/CN114364677A/zh active Pending
- 2020-07-14 CA CA3147266A patent/CA3147266C/en active Active
- 2020-07-14 JP JP2022502193A patent/JP7137733B2/ja active Active
- 2020-07-14 AU AU2020315210A patent/AU2020315210B2/en active Active
- 2020-07-14 MX MX2022000656A patent/MX2022000656A/es unknown
- 2020-07-14 EP EP20743357.4A patent/EP3999507A1/en active Pending
- 2020-07-14 CR CR20220018A patent/CR20220018A/es unknown
- 2020-07-14 KR KR1020227004825A patent/KR20220034862A/ko not_active Application Discontinuation
- 2020-07-14 CU CU2022000003A patent/CU20220003A7/es unknown
- 2020-07-14 WO PCT/IB2020/056605 patent/WO2021009676A1/en unknown
- 2020-07-15 UY UY0001038786A patent/UY38786A/es unknown
- 2020-07-16 TW TW109124069A patent/TWI755788B/zh active
-
2022
- 2022-01-06 CL CL2022000032A patent/CL2022000032A1/es unknown
- 2022-01-14 CO CONC2022/0000259A patent/CO2022000259A2/es unknown
- 2022-01-16 IL IL289877A patent/IL289877A/en unknown
- 2022-01-17 EC ECSENADI20223665A patent/ECSP22003665A/es unknown
- 2022-01-27 ZA ZA2022/01330A patent/ZA202201330B/en unknown
- 2022-05-06 US US17/738,074 patent/US11976064B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2020315210B2 (en) | 2023-01-12 |
CA3147266C (en) | 2023-09-12 |
CN114364677A (zh) | 2022-04-15 |
US11339159B2 (en) | 2022-05-24 |
TWI755788B (zh) | 2022-02-21 |
ZA202201330B (en) | 2022-10-26 |
CL2022000032A1 (es) | 2022-09-02 |
CU20220003A7 (es) | 2022-08-09 |
CR20220018A (es) | 2022-02-08 |
KR20220034862A (ko) | 2022-03-18 |
US20220274986A1 (en) | 2022-09-01 |
WO2021009676A8 (en) | 2022-03-03 |
JP2022534125A (ja) | 2022-07-27 |
JP7137733B2 (ja) | 2022-09-14 |
US11976064B2 (en) | 2024-05-07 |
WO2021009676A1 (en) | 2021-01-21 |
TW202116770A (zh) | 2021-05-01 |
CO2022000259A2 (es) | 2022-01-17 |
MX2022000656A (es) | 2022-02-16 |
BR112022000341A2 (pt) | 2022-04-12 |
IL289877A (en) | 2022-03-01 |
EP3999507A1 (en) | 2022-05-25 |
AU2020315210A1 (en) | 2022-02-03 |
ECSP22003665A (es) | 2022-02-25 |
CA3147266A1 (en) | 2021-01-21 |
UY38786A (es) | 2021-02-26 |
US20210017172A1 (en) | 2021-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20220342A1 (es) | Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll | |
PE20170403A1 (es) | COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER | |
PE20240584A1 (es) | Agonistas del receptor de glp-1 y usos de los mismos | |
PE20120172A1 (es) | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide | |
ECSP15029636A (es) | Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de beta-lactamasa | |
PE20160588A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
ECSP21073246A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
PE20091485A1 (es) | DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS | |
CO6300941A2 (es) | Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7 | |
ECSP10010349A (es) | Derivados de ftalazinona | |
AR067413A1 (es) | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer | |
UY27834A1 (es) | Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos. | |
PE20210160A1 (es) | Moduladores de nlrp3 | |
AR083358A1 (es) | Compuestos de furo[3,2-d]pirimidina | |
PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
PE20030477A1 (es) | ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
PE20130651A1 (es) | Derivados de imidazopiridina y su procedimiento de preparacion | |
PE20160589A1 (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a | |
AR076360A1 (es) | Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer | |
PE20141205A1 (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
PE20140571A1 (es) | Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas | |
PE20121556A1 (es) | 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina | |
PE20211868A1 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cancer | |
CO6410299A2 (es) | Derivados de triazolo [4,3-b] pridazina y sus usos para el cáncer de próstata |